Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written-informed consent.~* Subjects over 18 years of age, and less than 70 years old.~* Subjects with a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria.~* Subjects having experienced their first ALS symptoms within 18 months before recruitment/consent.~* FVC \> 70%~* Subjects must be medically suitable for study participation and of complying with all planned aspects of the protocol including blood sampling at the time of inclusion in the study.~Exclusion Criteria:~* Subjects with a clinically significant preexisting lung disease not attributable to ALS.~* Subjects with a diagnosis of other neurodegenerative diseases or diseases associated with dysfunction of the motor neurons that can confuse the diagnosis of ALS.~* Participation in other clinical trials, or the reception of any other investigational drug in the six months prior to the start of the study.~* Female subjects who are pregnant, currently breastfeeding, or attempting to conceive during the study.~* Difficult peripheral venous access precluding plasma exchange and inability to implement a viable alternative catheter to make continued performing plasma exchange visits according to protocol~* Any contraindication for plasma exchange or abnormal coagulation parameters according clinical criteria from apheresis team~* A history of frequent adverse reactions (serious or otherwise) to blood products.~* Hypersensitivity to albumin or allergies to any of the components of Albutein.~* Subjects that can not interrupt treatment with acetylsalicylic acid or oral anticoagulants~* Plasma creatinine \> 2mg/dl.~* Present a history of heart disease including ischemic heart disease or congestive heart failure.~* Presence of prior conduct disorders requiring pharmacologic intervention, with less than 3 months of stable treatment~* Any condition that complicates adherence to study protocol (illness with less than one year of expected survival, drug or alcohol abuse, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Albumin (Type: EXPERIMENTAL): Plasma exchange with Albumin

Based on this trial design, predict the completion outcome and termination type (if applicable).